Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NeuroEPO
- Development stage
- Phase 2
- Lead developer
- Center for Molecular Immunology
- Modality
- Recombinant Proteins and Enzymes, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Intranasal
01
Overview
NeuroEPO is a recombinant human erythropoietin (EPO) protein engineered to have low sialic acid content, which eliminates its hematopoietic (red blood cell–stimulating) activity while preserving and enhancing its neuroprotective properties. Developed for intranasal administration, this formulation allows direct delivery to the brain, bypassing the blood-brain barrier and minimizing systemic side effects. NeuroEPO acts by preventing oxidative damage, reducing neuroinflammation and apoptosis, and supporting neuronal survival and function. It has shown efficacy in preclinical models of neurological diseases such as Alzheimer's disease, Parkinson's disease, stroke, and ataxias. Clinical trials indicate that it can stabilize or improve cognitive function in patients with mild-to-moderate Alzheimer's disease and Parkinson's disease without causing hematological side effects[1][2][3][4][5][6][7][8].
- Brand names
- NeuralCIM
- Other names
- neuroeponeuroepo plus
02
Targets
Erythropoietin Receptor
Beyond the preview
Go deeper on NeuroEPO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuroEPO.